Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial
Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
Cardiovascular disease remains the most pressing healthcare issue for developed countries and
is becoming so for developing countries. There are a number of chronic therapies available
for long-term management of risk. Short term therapies for subjects with an acute event, such
as an episode of acute coronary syndrome (ACS), are focused on reperfusion and removing
thrombus but most subsequent events are caused by atherosclerotic plaque rupture at a
different site. There are no approved therapies that can rapidly reduce the burden of
unstable, inflamed plaque in the overall coronary vascular bed. HDL has multiple actions that
could lead to atherosclerotic plaque stabilization, such as rapid removal of large quantities
of cholesterol from the vasculature, improvement in endothelial function, protection against
oxidative damage and reduction in inflammation. This study will assess the effects of
CER-001, an ApoA-I-based HDL mimetic, on indices of atherosclerotic plaque progression and
regression as assessed by intravascular ultrasound (IVUS) measurements in patients with
(ACS).